alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp
Den här sidan gäller alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp. När flera former ingår i en ingrediensgrupp har varje form egna källor och forskningskopplingar.
Sidan är delvis färdig
Här finns forskningsunderlag. Läs källorna och vilket underlag varje avsnitt bygger på.
Vi saknar ännu en genomgång av grundbeskrivning, användning och begränsningar.
Sidan ger ingen samlad bedömning av nytta eller säkerhet, eller råd om dosering och behandling.
Vad är alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp?
En lättläst grundbeskrivning är ännu inte klar för den här formen. Se källans namn och kemiska uppgifter i kemisk fördjupning.
Användning · genomgång saknas ännu
Vi har ännu ingen källgranskad genomgång av användningen för den här formen. Produkter där ämnet har deklarerats finns längre ner på sidan.
Att ett ämne förekommer i en produkt eller har en viss roll i kroppen visar inte i sig vilken effekt ett tillskott har.
Vad säger forskningen?
Här finns 1 forskningssammanställning kopplad till den här ämnesposten. Läs vilken form och vilka deltagare som undersöktes innan du tolkar resultatet.
Urvalet består av artikelutdrag. Det är ännu ingen samlad bedömning av ingrediensens effekter.
Här kan du läsa sammanställningar från utvalda delar av forskningsartiklar. En enskild studie visar en del av bilden och ger inte i sig råd om att använda ett tillskott.
Glycan Specificity of P[19] Rotavirus and Comparison with Those of Related P Genotypes. ↗
Liu Y, Ramelot TA, Huang P, Liu Y, Li Z, Feizi T, Zhong W, Wu FT, Tan M, Kennedy MA, Jiang X.
Vad undersöktes?
- Hur undersöktes det?
- Through in vitro binding assays and saturation transfer difference (STD) nuclear magnetic resonance (NMR), we found that P[19] could bind mucin cores 2, 4, and 6, as well as type 1 histo-blood group antigens (HBGAs).
- Vilka undersöktes?
- expressed in E. coli BL21
- Vilken ämnesform?
- mucin core 2
- Vilken mängd användes?
- 200 μM protein and 6.0 mM ligand
- Hur länge pågick studien?
- Ingen uppgift i sammanställningen
Studieuppgifterna återges som originalcitat. Uppgifter som saknas här kan finnas i originalutdraget.
Vad kom studien fram till? · Utdrag 1
Författarna rapporterar att P[19] VP8* binder mucin core 2 (GlcNAcβ1-6GalNAc) i STD‑NMR‑experiment.
Vad behöver resultatet vägas mot?
Underlaget omfattar endast utvalda artikelstycken; någon samlad bedömning kan inte göras.
Läs de originalstycken som sammanställningen bygger på
AbstractThe P[19] genotype belongs to the P[II] genogroup of group A rotaviruses (RVs). However, unlike the other P[II] RVs, which mainly infect humans, P[19] RVs commonly infect animals (pigs), making P[19] unique for the study of RV diversity and host ranges. Through in vitro binding assays and saturation transfer difference (STD) nuclear magnetic resonance (NMR), we found that P[19] could bind mucin cores 2, 4, and 6, as well as type 1 histo-blood group antigens (HBGAs). The common sequences of these glycans serve as minimal binding units, while additional residues, such as the A, B, H, and Lewis epitopes of the type 1 HBGAs, can further define the binding outcomes and therefore likely the host ranges for P[19] RVs. This complex binding property of P[19] is shared with the other three P[II] RVs (P[4], P[6], and P[8]) in that all of them recognized the type 1 HBGA precursor, although P[4] and P[8], but not P[6], also bind to mucin cores. Moreover, while essential for P[4] and P[8] binding, the addition of the Lewis epitope blocked P[6] and P[19] binding to type 1 HBGAs. Chemical-shift NMR of P[19] VP8* identified a ligand binding interface that has shifted away from the known RV P-genotype binding sites but is conserved among all P[II] RVs and two P[I] RVs (P[10] and P[12]), suggesting an evolutionary connection among these human and animal RVs. Taken together, these data are important for hypotheses on potential mechanisms for RV diversity, host ranges, and cross-species transmission.
Expression and purification of VP8* proteins in Escherichia coli.The VP8* sequences (amino acids 46 to 231) from a human RV P[19] (GenBank accession number ) was expressed in E. coli BL21 and purified by glutathione S-transferase (GST) tag affinity purification, as described previously (). Recombinant VP8* proteins of other P[II] RVs (P[4], P[6], and P[8]) and a P[10] RV were also purified using the same expression system. 15N- or 15N,13C-labeled P[19] VP8* proteins were also made for the NMR studies using the same E. coli culture procedures, with the addition of 15N-minimal growth medium (22 mM KH2PO4, 50 mM Na2HPO4, 8.5 mM NaCl, 0.1 mM CaCl2, 2 mM MgSO4, 1× BME vitamins (catalog no. B6891; Sigma), 18 mM 15NH4Cl, and 22 mM glucose) or 15N,13C-minimal growth medium supplied with 22 mM [13C]glucose (). The GST tag of the labeled VP8* proteins was removed for the NMR study by cutting with thrombin (Sigma-Aldrich Co., St. Louis, MO), followed by fast protein liquid chromatography (FPLC) gel filtration to collect the VP8* protein fractions and concentration by ultracentrifugation. The purified VP8* proteins were stored at −80°C until needed.
STD NMR experiments.All saturation transfer difference (STD) NMR spectra were acquired in Shigemi Tubes (Shigemi, USA) with a Bruker 600-MHz Avance III spectrometer at 10°C using a conventional HCN probe and the TopSpin 3.1 pulse sequence STDDIFFGG19.3. The NMR sample for mucin core 2 in complex with P[19] VP8* was prepared with 200 μM protein and 6.0 mM ligand in a final volume of 300 μl of Tris NMR buffer. The LNFPI STD sample was prepared with 130 μM P[19] VP8* and 6.6 mM LNFPI in a final volume of 300 μl of phosphate NMR buffer. This results in total protein-ligand ratios of 1:35 and 1:50 for the mucin core 2 and LNFPI samples, respectively. The protein resonances were saturated at 0 ppm with a cascade of 40 Gaussian-shaped pulses with duration of 50 ms, resulting in a total saturation time of 2 s. The off-resonance saturation was applied to 30 ppm, and 1,024 experiments were acquired for each with a 5-s recycle delay. A spin-lock filter with strength of 10 kHz and duration of 100 to 200 ms was applied to suppress the broad protein resonance signals, and Watergate 3-9-19 was used to suppress the residual water signal. The STD spectra were obtained by subtracting the on-resonance spectrum from the off-resonance reference spectrum. STD amplification factors were determined by the equation (Io − Isat)/Io, where Io and Isat are the intensities of the signals in the reference and saturated spectra, respectively, and the normalized STD amplification percentage was determined by dividing by the largest STD amplification factor for each ligand. The protons with the largest STD amplification percentage along with data from the 2D STD TOCSY spectrum, which were used to resolve overlap from the 1D spectra, were used to assign the binding epitopes.
P[19] VP8* recognizes mucin cores and the type 1 HBGA precursor.The ligand binding specificity of the P[19] VP8* was further characterized by STD NMR. Data for a type 1 HBGA pentasaccharide, LNFPI (Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc), demonstrated that the extended type 1 chain of an internal Gal (Fucα1-2Galβ1-3GlcNAcβ1-3Gal) is also involved in the interaction with P[19] VP8*, in addition to the GlcNAc and the terminal (H) fucose ( and ). Similarly, STD NMR of P[19] VP8* with mucin core 2 showed a strong interaction with the disaccharide GlcNAcβ1-6GalNAc, in which the GlcNAc residue was highly involved ( and ).
Vad undersöktes?
- Hur undersöktes det?
- Through in vitro binding assays and saturation transfer difference (STD) nuclear magnetic resonance (NMR), we found that P[19] could bind mucin cores 2, 4, and 6, as well as type 1 histo-blood group antigens (HBGAs).
- Vilka undersöktes?
- expressed in E. coli BL21
- Vilken ämnesform?
- LNFPI
- Vilken mängd användes?
- 130 μM P[19] VP8* and 6.6 mM LNFPI
- Hur länge pågick studien?
- Ingen uppgift i sammanställningen
Studieuppgifterna återges som originalcitat. Uppgifter som saknas här kan finnas i originalutdraget.
Vad kom studien fram till? · Utdrag 2
Författarna rapporterar att P[19] VP8* binder LNFPI (type 1 HBGA‑pentasackarid) i STD‑NMR‑experiment.
Vad behöver resultatet vägas mot?
Underlaget omfattar endast utvalda artikelstycken; någon samlad bedömning kan inte göras.
Läs de originalstycken som sammanställningen bygger på
AbstractThe P[19] genotype belongs to the P[II] genogroup of group A rotaviruses (RVs). However, unlike the other P[II] RVs, which mainly infect humans, P[19] RVs commonly infect animals (pigs), making P[19] unique for the study of RV diversity and host ranges. Through in vitro binding assays and saturation transfer difference (STD) nuclear magnetic resonance (NMR), we found that P[19] could bind mucin cores 2, 4, and 6, as well as type 1 histo-blood group antigens (HBGAs). The common sequences of these glycans serve as minimal binding units, while additional residues, such as the A, B, H, and Lewis epitopes of the type 1 HBGAs, can further define the binding outcomes and therefore likely the host ranges for P[19] RVs. This complex binding property of P[19] is shared with the other three P[II] RVs (P[4], P[6], and P[8]) in that all of them recognized the type 1 HBGA precursor, although P[4] and P[8], but not P[6], also bind to mucin cores. Moreover, while essential for P[4] and P[8] binding, the addition of the Lewis epitope blocked P[6] and P[19] binding to type 1 HBGAs. Chemical-shift NMR of P[19] VP8* identified a ligand binding interface that has shifted away from the known RV P-genotype binding sites but is conserved among all P[II] RVs and two P[I] RVs (P[10] and P[12]), suggesting an evolutionary connection among these human and animal RVs. Taken together, these data are important for hypotheses on potential mechanisms for RV diversity, host ranges, and cross-species transmission.
Expression and purification of VP8* proteins in Escherichia coli.The VP8* sequences (amino acids 46 to 231) from a human RV P[19] (GenBank accession number ) was expressed in E. coli BL21 and purified by glutathione S-transferase (GST) tag affinity purification, as described previously (). Recombinant VP8* proteins of other P[II] RVs (P[4], P[6], and P[8]) and a P[10] RV were also purified using the same expression system. 15N- or 15N,13C-labeled P[19] VP8* proteins were also made for the NMR studies using the same E. coli culture procedures, with the addition of 15N-minimal growth medium (22 mM KH2PO4, 50 mM Na2HPO4, 8.5 mM NaCl, 0.1 mM CaCl2, 2 mM MgSO4, 1× BME vitamins (catalog no. B6891; Sigma), 18 mM 15NH4Cl, and 22 mM glucose) or 15N,13C-minimal growth medium supplied with 22 mM [13C]glucose (). The GST tag of the labeled VP8* proteins was removed for the NMR study by cutting with thrombin (Sigma-Aldrich Co., St. Louis, MO), followed by fast protein liquid chromatography (FPLC) gel filtration to collect the VP8* protein fractions and concentration by ultracentrifugation. The purified VP8* proteins were stored at −80°C until needed.
STD NMR experiments.All saturation transfer difference (STD) NMR spectra were acquired in Shigemi Tubes (Shigemi, USA) with a Bruker 600-MHz Avance III spectrometer at 10°C using a conventional HCN probe and the TopSpin 3.1 pulse sequence STDDIFFGG19.3. The NMR sample for mucin core 2 in complex with P[19] VP8* was prepared with 200 μM protein and 6.0 mM ligand in a final volume of 300 μl of Tris NMR buffer. The LNFPI STD sample was prepared with 130 μM P[19] VP8* and 6.6 mM LNFPI in a final volume of 300 μl of phosphate NMR buffer. This results in total protein-ligand ratios of 1:35 and 1:50 for the mucin core 2 and LNFPI samples, respectively. The protein resonances were saturated at 0 ppm with a cascade of 40 Gaussian-shaped pulses with duration of 50 ms, resulting in a total saturation time of 2 s. The off-resonance saturation was applied to 30 ppm, and 1,024 experiments were acquired for each with a 5-s recycle delay. A spin-lock filter with strength of 10 kHz and duration of 100 to 200 ms was applied to suppress the broad protein resonance signals, and Watergate 3-9-19 was used to suppress the residual water signal. The STD spectra were obtained by subtracting the on-resonance spectrum from the off-resonance reference spectrum. STD amplification factors were determined by the equation (Io − Isat)/Io, where Io and Isat are the intensities of the signals in the reference and saturated spectra, respectively, and the normalized STD amplification percentage was determined by dividing by the largest STD amplification factor for each ligand. The protons with the largest STD amplification percentage along with data from the 2D STD TOCSY spectrum, which were used to resolve overlap from the 1D spectra, were used to assign the binding epitopes.
P[19] VP8* recognizes mucin cores and the type 1 HBGA precursor.The ligand binding specificity of the P[19] VP8* was further characterized by STD NMR. Data for a type 1 HBGA pentasaccharide, LNFPI (Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc), demonstrated that the extended type 1 chain of an internal Gal (Fucα1-2Galβ1-3GlcNAcβ1-3Gal) is also involved in the interaction with P[19] VP8*, in addition to the GlcNAc and the terminal (H) fucose ( and ). Similarly, STD NMR of P[19] VP8* with mucin core 2 showed a strong interaction with the disaccharide GlcNAcβ1-6GalNAc, in which the GlcNAc residue was highly involved ( and ).
Artikelns licens · ActiQs sammanfattningar och texturval är bearbetningar av källan.
Företagsuppgifter och hälsopåståenden · genomgång saknas ännu
Vi har ännu ingen källbunden genomgång av företagens påståenden för den här formen.
Ett företags beskrivning behöver läsas som företagets uppgift. För att bedöma stödet behöver man även se originalstudierna, den undersökta ämnesformen och resultatens begränsningar.
Begränsningar och försiktighetsuppgifter · genomgång saknas ännu
Grundbeskrivningen förklarar ämnet. Den bedömer inte nytta eller säkerhet vid användning av ett tillskott. Studieresultat för ett salt, en jon eller en annan form kan inte automatiskt överföras till den här formen.
En genomgång av källbelagda försiktighetsuppgifter saknas ännu. Sidan ger därför ingen samlad säkerhetsbedömning eller råd om dosering och behandling.
Kemisk fördjupning · fler namn, identifierare och källuppgifter
Kemiska källuppgifter
- Molekylformel
- C32H55NO25
- Laddning
- 0
- Molekylmassa
- 853.774
- InChIKey
- FZIVHOUANIQOMU-YIHIYSSUSA-N
- SMILES
- CC(=O)N[C@H]1[C@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](O[C@H]3[C@H](O)[C@@H](O)C(O)O[C@@H]3CO)[C@@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]1O
- Källans klassificering
- 3:STAR
Synonymer
EXACT är källans exakta synonym. RELATED, BROAD och NARROW kan vara relaterade, bredare eller snävare benämningar. Sådana namn innebär inte automatiskt samma identitet.
- (Gal)2 (Glc)1 (GlcNAc)1 (LFuc)1 RELATED
- 6-deoxy-alpha-L-galactopyranosyl-(1->2)-beta-D-galactopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1->3)-beta-D-galactopyranosyl-(1->4)-D-glucopyranose RELATED
- Fucalpha1-2Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc RELATED
- H type I RELATED
- LNF-I RELATED
- LNFP I RELATED
- LNFPI RELATED
- Lacto-N-fucopentaitol I RELATED
- Lacto-N-fucopentaose I RELATED
- alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc RELATED
- alpha-L-fucopyranosyl-(1->2)-beta-D-galactopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1->3)-beta-D-galactopyranosyl-(1->4)-D-glucopyranose EXACT
- alpha-L-fucopyranosyl-(1->2)-beta-D-galactopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1->3)-beta-D-galactopyranosyl-(1->4)-D-glucopyranose RELATED
- alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-D-glucose RELATED
Definition
A linear amino pentasaccharide comprising one fucose, two galactose, one glucosamine and one glucose unit (at the reducing end), linked as shown.
Källans text; inga egna slutsatser har lagts till.Identifierare i källan
- glygen: G01650PH
- glytoucan: G01650PH
- kegg.glycan: G00535
- pubmed: 11425797
- pubmed: 15158661
- pubmed: 15262925
- pubmed: 1695678
- pubmed: 2413844
- pubmed: 27558427
- pubmed: 2776132
- pubmed: 3274083
- pubmed: 3397933
- pubmed: 8675304
- pubmed: 9271064
- reaxys: 6050700
Relationer och ämnesformer
- is_a · glucosamine oligosaccharide
- is_a · amino pentasaccharide
Besläktade ämnen och beståndsdelar
Följ hur ämnet hänger ihop med andra kemiska identiteter.
Fördjupning · ämnesklasser och roller
- glucosamine oligosaccharide
Tillhör ämnesklassen
Kopplingens underlag
alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp → glucosamine oligosaccharide
Originalregister
is_a · a160b0f4-cb3c-48cd-88b3-51a2d119c323 - amino pentasaccharide
Tillhör ämnesklassen
Kopplingens underlag
alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp → amino pentasaccharide
Originalregister
is_a · a160b0f4-cb3c-48cd-88b3-51a2d119c323 - alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp
Ämne i denna klass
Kopplingens underlag
alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp → alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp
Originalregister
is_a · 162a9e24-bfbd-4c3e-98d0-1d77630d1cd0
Relationer beskriver källans kemiska struktur eller klassificering. Ämnena behåller separata identiteter. Detta innebär inte samma innehåll, dosering, effekt eller säkerhet.
Utforska ingrediensens kopplingar
Följ länkarna till produkter, publikationer och källuppgifter för just den här formen.
Se kopplingarna i ett diagram →Publikationer i källan
ChEBI hänvisar till 11 PubMed-publikationer för den här posten. Kopplingen är en källhänvisning och innebär ingen egen slutsats om effekt eller säkerhet.
11 publikationsposter har hämtats hittills. Registret fylls automatiskt.
Glycan Specificity of P[19] Rotavirus and Comparison with Those of Related P Genotypes.
Liu Y, Ramelot TA, Huang P, Liu Y, Li Z, Feizi T, Zhong W, Wu FT, Tan M, Kennedy MA, Jiang X.
J Virol · research-article; journal article · DOI 10.1128/jvi.01494-16Molecular cloning and characterization of Bifidobacterium bifidum 1,2-alpha-L-fucosidase (AfcA), a novel inverting glycosidase (glycoside hydrolase family 95).
Katayama T, Sakuma A, Kimura T, Makimura Y, Hiratake J, Sakata K, Yamanoi T, Kumagai H, Yamamoto K.
J Bacteriol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/jb.186.15.4885-4893.2004The third chains of living organisms--a trail of glycobiology that started from the third floor of building 4 in NIH.
Kobata A.
Arch Biochem Biophys · review; journal article · DOI 10.1016/j.abb.2004.01.023Fucosylated human milk oligosaccharides vary between individuals and over the course of lactation.
Chaturvedi P, Warren CD, Altaye M, Morrow AL, Ruiz-Palacios G, Pickering LK, Newburg DS.
Glycobiology · research support, u.s. gov't, p.h.s.; journal article · DOI 10.1093/glycob/11.5.365Structural analysis of permethylated oligosaccharides by electrospray tandem mass spectrometry.
Viseux N, de Hoffmann E, Domon B.
Anal Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/ac961285uJämför med en annan ingrediens →
Produkter som deklarerar den här formen
Här finns produkter som har kopplats till just den här formen. Saknade träffar betyder inte att formen saknas i alla produkter.
Ämnet i källregistren
Utforska ingredienslistor och EU-register med tillgängliga kopplingar till detta ämne.
Visa källposter för ämnet →Källversioner
ChEBI 255 ·
ChEBI · EMBL-EBI · CC BY 4.0 · CC BY 4.0
Öppna originalkällan →